{"id":21213,"date":"2024-03-14T11:50:53","date_gmt":"2024-03-14T11:50:53","guid":{"rendered":"https:\/\/clinlabint.com\/?p=21213"},"modified":"2024-03-14T13:24:55","modified_gmt":"2024-03-14T13:24:55","slug":"novartis-to-acquire-calypso-biotech-and-caly-002-therapeutic-antibody","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/novartis-to-acquire-calypso-biotech-and-caly-002-therapeutic-antibody\/","title":{"rendered":"Novartis to acquire Calypso Biotech and CALY-002 therapeutic antibody"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Novartis to acquire Calypso Biotech and CALY-002 therapeutic antibody<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Novartis will acquire Calypso Biotech, a developer of Interleukin15 (IL-15) targeted therapies, for US$250 million plus a further $175 million based on the achievement of certain predetermined milestones.<\/h3>\n

<\/p>\n

Calypso, a spin-out from Merck, is focused on the research and development of monoclonal antibodies for an array of autoimmune indications, with expertise in IL-15 biology. IL-15 is a broad, untapped immune axis that controls barrier function and downstream immune cascades in many chronic autoimmune diseases. Calypso\u2019s lead product candidate, CALY-002, is a potential best-in-class therapeutic antibody that binds to and neutralizes Interleukin-15.<\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n
\"\"<\/div><\/div><\/div>
\n

Structure of human Interleukin15<\/em><\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n

The acquisition gives Novartis full rights to CALY-002. Novartis intends to further explore CALY-002 across a wide variety of auto\u00adimmune indications with high unmet medical need. CALY-002 is currently being evaluated in a Phase 1b trial in patients with Celiac Disease and Eosinophilic Esophagitis.<\/p>\n

Commenting on the acquisition, Alain Vicari, Chief Executive Officer & Co-Founder, Calypso, said: \u201cWe are excited for this transaction with Novartis, a company with relentless commitment to the development of innovative therapies for autoimmune conditions. As part of the Novartis portfolio, CALY-002 is in the best position to be developed effectively, so that it can promptly address unmet medical needs in multiple indications.\u201d<\/p>\n

Bernard Coulie, Chairman, Calypso, commented: \u201cThe transaction with Novartis constitutes the high point in the development path of CALY-002 for the Calypso team. Calypso has established a significantly de-risked profile for CALY-002 as a potential best-in-class therapeutic anti-IL-15 antibody\u201d<\/p>\n

Richard Siegel, Head of Immunology Research at Novartis, commented: \u201cNovartis is committed to bringing innovative treatment options forward for patients living with immunological diseases. We\u2019re thrilled to add Calypso\u2019s potential best-in-class antibody to our Immunology pipeline and explore it in a spectrum of autoimmune indications.\u201d<\/p>\n<\/div><\/section>
\n